Company Registration No. 10048994 (England and Wales)
Diagnostics 2016 Limited
Unaudited financial statements
for the year ended 30 November 2025
Pages for filing with the registrar
Diagnostics 2016 Limited
Contents
Page
Statement of financial position
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 8
Diagnostics 2016 Limited
Statement of financial position
As at 30 November 2025
1
2025
2024
Notes
£
£
£
£
Fixed assets
Investments
4
4,855,000
4,854,000
Current assets
Debtors
5
106
-
0
Cash at bank and in hand
775
4,215
881
4,215
Creditors: amounts falling due within one year
6
(1,370,650)
(1,437,880)
Net current liabilities
(1,369,769)
(1,433,665)
Total assets less current liabilities
3,485,231
3,420,335
Creditors: amounts falling due after more than one year
7
(2,368,361)
(2,234,593)
Net assets
1,116,870
1,185,742
Capital and reserves
Called up share capital
8
8,395
8,395
Share premium account
831,105
831,105
Other reserves
92,295
271,063
Profit and loss reserves
185,075
75,179
Total equity
1,116,870
1,185,742

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Diagnostics 2016 Limited
Statement of financial position (continued)
As at 30 November 2025
2
The financial statements were approved by the board of directors and authorised for issue on 29 April 2026 and are signed on its behalf by:
Paul Betts
Director
Company Registration No. 10048994
Diagnostics 2016 Limited
Statement of changes in equity
For the year ended 30 November 2025
3
Share capital
Share premium account
Capital Contribution
Other reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
£
Balance at 1 December 2023
8,395
831,105
399,432
37,156
(236,167)
1,039,921
Year ended 30 November 2024:
Profit and total comprehensive income for the year
-
-
-
-
311,346
311,346
Issue of share capital
8
745
-
0
-
-
-
745
Reduction of shares
8
(745)
-
0
-
-
-
0
(745)
Movement of discounted loan
-
-
(165,525)
-
-
(165,525)
Balance at 30 November 2024
8,395
831,105
233,907
37,156
75,179
1,185,742
Year ended 30 November 2025:
Profit and total comprehensive income for the year
-
-
-
-
109,896
109,896
Movement of discounted loan
-
-
(178,768)
-
-
(178,768)
Balance at 30 November 2025
8,395
831,105
55,139
37,156
185,075
1,116,870
Diagnostics 2016 Limited
Notes to the financial statements
For the year ended 30 November 2025
4
1
Accounting policies
Company information

Diagnostics 2016 Limited is a private company limited by shares incorporated in England and Wales. The registered office is c/o Burgess Diagnostics Limited, Oak House, 317 Golden Hill Lane, Leyland, Lancashire, PR25 2YJ.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Diagnostics 2016 Limited
Notes to the financial statements (continued)
For the year ended 30 November 2025
1
Accounting policies (continued)
5
1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Diagnostics 2016 Limited
Notes to the financial statements (continued)
For the year ended 30 November 2025
1
Accounting policies (continued)
6
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2
Critical accounting judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
Diagnostics 2016 Limited
Notes to the financial statements (continued)
For the year ended 30 November 2025
7
4
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
4,855,000
4,854,000

The directors consider that there has been no material change to the value as at the balance sheet date.

Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 December 2024
4,854,000
Additions
1,000
At 30 November 2025
4,855,000
Carrying amount
At 30 November 2025
4,855,000
At 30 November 2024
4,854,000

Due to a simplification of the group structure, Diagnostics 2016 Limited is now the direct parent company of Burgess Diagnostics Limited.

5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
106
-
0
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
-
0
152,344
Amounts owed to group undertakings
1,370,650
1,274,588
Corporation tax
-
0
7,948
Other taxation and social security
-
0
3,000
1,370,650
1,437,880
Diagnostics 2016 Limited
Notes to the financial statements (continued)
For the year ended 30 November 2025
8
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Other creditors
2,368,361
2,234,593

Other creditors are secured by way of a fixed and floating charge over the assets of the company, and over the assets of its subsidiary Burgess Diagnostics Limited.

Included within other creditors above are loan notes of £2,468,500, which have been discounted to NPV at 8%. The accrued loan note interest and right to future interest was irrevocably waived on 1 December 2022 by the loan note holders. Further, the loan note principal will only be considered for repayment once sufficient funds are held by the company. As this is not expected to occur in the foreseeable future, the loan note principal is considered by the loan note holders to form part of the capital base of the company.

 

8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A ordinary shares of 1p each
839,500
839,500
8,395
8,395
9
Financial commitments, guarantees and contingent liabilities

The company is party to a cross-company guarantee with its subsidiary company Burgess Diagnostics Limited in respect of non-bank borrowings existing in the group totalling £2,423,500 (2024: £2,468,500).

 

Two fixed and floating charges as secured against the Company by HSBC were satisfied in the year. The bank borrowings in the year ended 30 November 2024 of £152,343 were cleared in the year.

 

As at the year end, the directors consider the probability of default remote and accordingly, no liability is recognised on the balance sheet.

10
Parent company

The company’s ultimate parent undertaking and controlling party is Solingen Private Equity No 1 LP.

11
Related party transactions
Balances with related parties

The following amounts were outstanding at the reporting end date:

Amounts owed by
Amounts owed to
related parties
related parties
2025
2024
2025
2024
£
£
£
£
Burgess Diagnostics Limited
-
-
1,370,468
1,274,588
2025-11-302024-12-01falsefalsefalse29 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityPaul BettsRobin WomersleyHadfieldMary Bronserud100489942024-12-012025-11-30100489942025-11-30100489942024-11-3010048994core:WithinOneYear2025-11-3010048994core:WithinOneYear2024-11-3010048994core:AfterOneYear2025-11-3010048994core:AfterOneYear2024-11-3010048994core:CurrentFinancialInstruments2025-11-3010048994core:CurrentFinancialInstruments2024-11-3010048994core:ShareCapital2025-11-3010048994core:ShareCapital2024-11-3010048994core:SharePremium2025-11-3010048994core:SharePremium2024-11-3010048994core:OtherMiscellaneousReserve2025-11-3010048994core:OtherMiscellaneousReserve2024-11-3010048994core:RetainedEarningsAccumulatedLosses2025-11-3010048994core:RetainedEarningsAccumulatedLosses2024-11-3010048994core:ShareCapital2023-11-3010048994core:SharePremium2023-11-3010048994core:RetainedEarningsAccumulatedLosses2023-11-3010048994core:ShareCapitalOrdinaryShareClass12025-11-3010048994core:ShareCapitalOrdinaryShareClass12024-11-3010048994bus:Director12024-12-012025-11-3010048994core:RetainedEarningsAccumulatedLosses2023-12-012024-11-30100489942023-12-012024-11-3010048994core:RetainedEarningsAccumulatedLosses2024-12-012025-11-3010048994core:ShareCapital2023-12-012024-11-3010048994core:SharePremium2023-12-012024-11-3010048994core:CurrentFinancialInstrumentscore:WithinOneYear2025-11-3010048994core:CurrentFinancialInstrumentscore:WithinOneYear2024-11-3010048994core:Non-currentFinancialInstruments2025-11-3010048994core:Non-currentFinancialInstruments2024-11-3010048994bus:OrdinaryShareClass12024-12-012025-11-3010048994bus:OrdinaryShareClass12025-11-3010048994bus:OrdinaryShareClass12024-11-3010048994core:Subsidiary12024-12-012025-11-3010048994bus:PrivateLimitedCompanyLtd2024-12-012025-11-3010048994bus:SmallCompaniesRegimeForAccounts2024-12-012025-11-3010048994bus:FRS1022024-12-012025-11-3010048994bus:AuditExemptWithAccountantsReport2024-12-012025-11-3010048994bus:Director22024-12-012025-11-3010048994bus:Director32024-12-012025-11-3010048994bus:Director42024-12-012025-11-3010048994bus:FullAccounts2024-12-012025-11-30xbrli:purexbrli:sharesiso4217:GBP